Upgrade Alert for AMAG Pharmaceuticals (AMAG)
AMAG Pharmaceuticals (NASDAQ:AMAG) was upgraded from Market Perform to Outperform at Leerink today. The stock closed yesterday at $15.45 on volume of 49,000 shares, below average daily volume of 88,000.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
There is potential upside of 7.9% for shares of AMAG Pharmaceuticals based on a current price of $15.45 and an average consensus analyst price target of $16.67. The stock should discover initial support at its 200-day moving average (MA) of $15.43 and subsequent support at its 50-day MA of $15.09.
In the past 52 weeks, shares of AMAG Pharmaceuticals have traded between a low of $12.43 and a high of $18.50 and closed yesterday at $15.45, which is 24% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 0.2%.
SmarTrend is monitoring the recent change of momentum in AMAG Pharmaceuticals. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of AMAG Pharmaceuticals in search of a potential trend change.
Keywords: analyst upgrades/downgrades amag pharmaceuticals